The GI Company to Present at the BIO Europe 2008 International Convention

The GI Company, Inc., a privately held developer of gastrointestinal therapeutics, today announced that Dr. Nicholas Barker, President and Chief Executive Officer, will make a corporate presentation on Wednesday, November 19, 2008 at 9:30 a.m. in Room I, Level 3 of the m:con Congress Center Rosengarten at the BIO Europe 2008 International Convention, taking place November 17-19, 2008 in Mannheim, Germany.

Framingham, MA (PRWEB) November 6, 2008 - The GI Company, Inc., a privately held developer of gastrointestinal therapeutics, today announced that Dr. Nicholas Barker, President and Chief Executive Officer, will make a corporate presentation on Wednesday, November 19, 2008 at 9:30 a.m. in Room I, Level 3 of the m:con Congress Center Rosengarten at the BIO Europe 2008 International Convention, taking place November 17-19, 2008 in Mannheim, Germany. Dr. Barker will also participate in the BIO Business Forum and will be available for one-on-one meetings during the convention. His presentation will include a summary of results from a Phase II clinical study designed to evaluate the safety and efficacy of the company's lead clinical candidate, Intestinal Trefoil Factor (rhITF), in development for the prophylaxis of chemotherapy-induced oral mucositis. These data were previously presented for peer review by Dr. Barker at the American Society of Clinical Oncology (ASCO) 2008 Annual Meeting. For more information, visit http://www.bio2008.org/

About The GI Company, Inc.

The GI Company is a clinical-stage biotechnology company highly specialized at developing drugs to treat gastrointestinal and related diseases. The company's lead clinical candidate is Intestinal Trefoil Factor (rhITF), which is being developed for the treatment of oral mucositis. The GI Company also has clinical rhITF programs in a variety of conditions such as erosive gastritis (NSAID induced), ulcerative colitis and corneal wound healing, as well as pre-clinical development projects in Enteritis/Proctitis, Inflammatory Bowel Disease, Erosive Gastroesophageal Reflux Disease, Peptic Ulcer Disease and gastrointestinal motility disorders. The company is funded through a private equity financing consortium and has raised over $20M to date. The GI Company has retained Burrill & Company to assist in the selection of a transaction partner for its clinical programs. For more information, please visit www.thegicompany.com.

Contact:

Jodi Rutkowski

Manager, Public Relations

The GI Company, Inc.

jodi.rutkowski(at)thegicompany.com

###